| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $95M | ||
| $91M |
Buys | $226,455 | 7 | 100 |
Sells | $0 | 0 | 0 |
| Nijhawan Pardeep | Chief Executive Officer | 6 | $223,315 | 0 | $0 | $223,315 |
| Brooks Michael J | President | 1 | $3,140 | 0 | $0 | $3,140 |
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Over the last 12 months, insiders at Edesa Biotech, Inc. have bought $226,455 and sold $0 worth of Edesa Biotech, Inc. stock.
On average, over the past 5 years, insiders at Edesa Biotech, Inc. have bought $92,502 and sold $787,716 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Nijhawan Pardeep (Chief Executive Officer) — $223,315. Brooks Michael J (President) — $3,140.
The last purchase of 10,000 shares for transaction amount of $39,000 was made by Nijhawan Pardeep (Chief Executive Officer) on 2026‑03‑05.
| 2026-03-05 | Nijhawan Pardeep | Chief Executive Officer | 10,000 0.1266% | $3.90 | $39,000 | +98.34% | ||
| 2026-03-04 | Nijhawan Pardeep | Chief Executive Officer | 10,000 0.1194% | $4.26 | $42,560 | +67.21% | ||
| 2026-03-03 | Nijhawan Pardeep | Chief Executive Officer | 10,000 0.1907% | $3.63 | $36,300 | +62.87% | ||
| 2026-03-02 | Nijhawan Pardeep | Chief Executive Officer | 3,000 0.0342% | $2.09 | $6,280 | +208.33% | ||
| 2026-02-27 | Nijhawan Pardeep | Chief Executive Officer | 30,000 0.3632% | $2.22 | $66,696 | +219.32% | ||
| 2026-02-26 | Nijhawan Pardeep | Chief Executive Officer | 20,571 0.251% | $1.58 | $32,480 | +352.90% | ||
| 2026-02-26 | Brooks Michael J | President | 2,000 0.0243% | $1.57 | $3,140 | +352.90% | ||
| 2024-03-25 | Nijhawan Pardeep | Chief Executive Officer | 5,000 0.1509% | $4.00 | $20,000 | +1.55% | ||
| 2023-01-10 | Sale | van der Velden Peter | director | 152,345 0.8038% | $2.63 | $401,368 | -65.60% | |
| 2023-01-09 | Sale | van der Velden Peter | director | 145,129 0.7355% | $2.66 | $386,348 | -67.30% | |
| 2022-06-30 | Pardeep Nijhawan Medicine Professional Corp | Chief Executive Officer | 20,000 0.165% | $1.60 | $32,078 | -29.19% | ||
| 2022-06-29 | Brooks Michael J | President | 3,000 0.0196% | $1.49 | $4,483 | -22.30% | ||
| 2022-06-16 | Brooks Michael J | President | 3,000 0.0189% | $1.61 | $4,817 | -24.24% | ||
| 2022-05-27 | Pardeep Nijhawan Medicine Professional Corp | Chief Executive Officer | 5,000 0.0317% | $1.92 | $9,599 | -28.57% | ||
| 2022-05-25 | Brooks Michael J | President | 3,500 0.0226% | $1.74 | $6,090 | -19.54% | ||
| 2022-05-24 | Pardeep Nijhawan Medicine Professional Corp | Chief Executive Officer | 2,000 0.0133% | $1.80 | $3,600 | -19.43% | ||
| 2022-03-31 | Pardeep Nijhawan Medicine Professional Corp | Chief Executive Officer | 2,000 0.013% | $2.99 | $5,972 | -45.45% | ||
| 2022-03-30 | Pardeep Nijhawan Medicine Professional Corp | Chief Executive Officer | 2,000 0.0148% | $3.05 | $6,098 | -45.30% | ||
| 2022-03-29 | Pardeep Nijhawan Medicine Professional Corp | Chief Executive Officer | 2,000 0.0147% | $3.02 | $6,034 | -44.75% | ||
| 2022-03-18 | Pardeep Nijhawan Medicine Professional Corp | Chief Executive Officer | 2,000 0.0138% | $3.85 | $7,699 | -58.48% |
| Nijhawan Pardeep | Chief Executive Officer | 402702 4.5288% | $2.2M | 12 | 0 | +7.13% |
| Brooks Michael J | President | 226870 2.5514% | $1.24M | 11 | 0 | <0.0001% |
| Pardeep Nijhawan Medicine Professional Corp | Chief Executive Officer | 594812 6.6893% | $3.25M | 11 | 0 | <0.0001% |
| van der Velden Peter | director | 150275 1.69% | $820,501.50 | 1 | 2 | |
| MORSE DANIEL E. | 20741 0.2333% | $113,245.86 | 0 | 7 | ||
| JOHNSON LORIN K | director | 8524 0.0959% | $46,541.04 | 1 | 0 | |
| Sistilli Carlo | director | 2436 0.0274% | $13,300.56 | 1 | 0 | |
| OAKES FRANK R. | director | 0 0% | $0 | 0 | 4 |
$2,542,362 | 111 | 11.81% | $54.57M | |
$155,630,608 | 79 | -24.53% | $54.18M | |
$693,326 | 47 | -16.18% | $49.93M | |
$4,898,715 | 46 | 40.75% | $57.34M | |
$24,478,755 | 37 | -34.59% | $56.18M | |
$26,786,140 | 22 | -18.62% | $56.93M | |
Edesa Biotech, Inc. (EDSA) | $226,127 | 22 | -27.62% | $48.55M |
$3,556,951 | 18 | 9.64% | $41.07M | |
$277,862 | 15 | 59.79% | $58.09M | |
$31,610,161 | 9 | -73.83% | $46.07M | |
$45,000,000 | 6 | -31.22% | $54.73M | |
$208,889 | 5 | 44.22% | $46.08M | |
$5,306,958 | 5 | 11.70% | $44.15M | |
$104,699 | 5 | -12.61% | $38.49M | |
$657,791 | 4 | -52.05% | $37.18M | |
$67,369,250 | 3 | -22.09% | $45.13M | |
$4,999,995 | 1 | -67.50% | $48.99M | |
$4,030 | 1 | 9.14% | $43.52M | |
$150,000 | 1 | 5.48% | $45.8M |
| Increased Positions | 11 | +40.74% | 263,786 | +9.17% |
| Decreased Positions | 9 | -33.33% | 87,821 | -3.05% |
| New Positions | 6 | New | 221,548 | New |
| Sold Out Positions | 6 | Sold Out | 79,264 | Sold Out |
| Total Postitions | 29 | +7.41% | 3M | +6.12% |
| Rubric Capital Management Lp | $1,031.00 | 8.59% | 687,500 | 0 | 0% | 2025-09-30 |
| Stonepine Capital Management, Llc | $1,031.00 | 8.59% | 687,500 | +687,500 | New | 2025-09-30 |
| Velan Capital Investment Management Lp | $1,031.00 | 8.59% | 687,500 | 0 | 0% | 2025-09-30 |
| Nantahala Capital Management, Llc | $938.00 | 7.81% | 625,000 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $68.00 | 0.57% | 45,543 | +29,679 | +187.08% | 2025-09-30 |
| Geode Capital Management, Llc | $68.00 | 0.57% | 45,234 | +17,278 | +61.8% | 2025-09-30 |
| Commonwealth Equity Services, Llc | $56.00 | 0.47% | 37,548 | +2,545 | +7.27% | 2025-09-30 |
| Renaissance Technologies Llc | $38.00 | 0.31% | 25,000 | +25,000 | New | 2025-09-30 |
| Susquehanna International Group, Llp | $22.00 | 0.18% | 14,610 | +14,610 | New | 2025-09-30 |
| Citadel Advisors Llc | $21.00 | 0.18% | 14,032 | -9,482 | -40.33% | 2025-09-30 |